Capricor to Present Deramiocel HOPE-3 Data at WMS 2026
SAN DIEGO, Calif. — September 17, 2026 Capricor Therapeutics announced that 24-month data from the HOPE-3 Phase 3 trial...
DMD
Advertisement
Dyne Therapeutics Advances Four DMD Exon-Skipping Candidates
Waltham, Mass., September 3, 2026 Dyne Therapeutics announced that it will present new preclinical data supporting the development of...
NewBiologix Partners With Synastra on DMD Gene Therapy Manufacturing
LAUSANNE, Switzerland, September 2, 2026 NewBiologix S.A. has entered into an agreement with Synastra Biotechnology Inc. to develop a...
Capricor Advances Deramiocel as FDA Review Continues
SAN DIEGO, August 13, 2026 Capricor Therapeutics continues to advance Deramiocel (CAP-1002) for Duchenne muscular dystrophy (DMD) as the...
Italfarmaco Secures Managed Entry Agreement for Duvyzat in Georgia
MILAN, Italy, July 31, 2026 talfarmaco S.p.A. announced a managed entry agreement with the Georgian Ministry of Health to...
Advertisements
Dyne Therapeutics Advances DMD Program with FDA Acceptance
WALTHAM, Mass., July 20, 2026 Dyne Therapeutics, Inc. (Nasdaq: DYN) announced that the U.S. Food and Drug Administration (FDA)...
Santhera Expands AGAMREE Distribution Across Central Asia and Caucasus
PRATTELN, Switzerland, July 13, 2026 Santhera Pharmaceuticals announced the expansion of its exclusive distribution agreement with Biomedica, extending commercial...
Satellos Reports Positive Six-Month SAT-3247 Data
TORONTO, July 8, 2026 Satellos Bioscience Inc. announced encouraging six-month interim data from its ongoing Phase 2 TRAILHEAD clinical...
Grünenthal Receives Dual FDA Designations for Tegacorat in DMD
AACHEN, Germany, July 8, 2026 Grünenthal has announced that the U.S. Food and Drug Administration (FDA) has granted both...
Santhera Reports Positive Phase 1 AGAMREE Data
Pratteln, Switzerland, July 1, 2026 Santhera Pharmaceuticals announced positive topline findings from a Phase 1 clinical study of AGAMREE®...
Advertisement
